-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai, September 24, 2021/PRNewswire/ - Recently, at the 2021 European Society of Medical Oncology (ESMO) annual meeting, the national original innovative drug punabulin announced its effectiveness in the field of advanced non-small cell lung cancer (NSCLC).
Pranabrin belongs to a new type of "boosting drug" (a drug that increases the number of white blood cells) of the GEF-H1 (guanine nucleotide exchange factor) activator, and can also prevent the bone marrow neutrophil damage induced by chemotherapy drugs.
According to the statistics of The Lancet, the number of new cancer patients in China in recent years has reached about 4.
In September 2020, Pranabrin received the dual designation of "Breakthrough Therapy" in the field of neutropenia (CIN) treatment in China and the United States due to the excellent data in the PROTECTIVE-2 (106 study) study
Pranabrin can also activate the immune defense protein guanine nucleotide exchange factor (GEF-H1).
The DUBLIN-3 study announced at this conference is a new exploration of ponabrin in the field of tumor treatment
The average progression-free survival (PFS) was 6.
In terms of safety, the combination treatment group was well tolerated, and compared with the control group, patients had better quality of life
Academician Sun Yan, one of the leaders of the DUBLIN-3 study, said that the DUBLIN-3 study showed good OS (overall survival) benefits and was the first drug with a new mechanism in the second-line NSCLC since nivolumab was launched in 2015.
It is reported that the study of Pranabrin combined with PD-1 and CTLA-4 inhibitors in the treatment of small cell lung cancer (SCLC) has shown a gratifying effect.
In April 2021, Pranabrin has submitted a new drug marketing application for neutropenia (CIN) to the Center for Drug Evaluation of the National Medical Products Administration and the FDA
Source: Jiangsu Hengrui Pharmaceutical Co.
